Keyword: Ozempic (semaglutide)
Novo Nordisk is investing nearly $100 million in its massive site in Denmark to make next-generation insulins and other drugs.
Novo turned in its FDA application on Wednesday for oral semaglutide, which analysts believe will eventually pull in billions of dollars annually.
Novo's oral semaglutide could shake up the coverage landscape as it touches on both the branded orals and the injectable GLP-1s, one analyst says.
Analysts believe Novo's oral semaglutide will pull in blockbuster sales, and the company is using a priority review voucher to get to market faster.
Novo Nordisk’s oral semaglutide is heading toward a market shake-up. And the company wants to see that happen sooner rather than later.
All eyes are on Eli Lilly’s Trulicity as it faces down new competition. But the drugmaker just notched an important trial win that shows it can hang with its rival.
Novo will reduce headcount by 1,300 by the end of 2018 to feed resources into its drug launches and marketing, as well as R&D.
Novo Nordisk rolled out more data for its next great hope: oral semaglutide, which would be the only pill in a hotly competitive GLP-1 class.
Novo Nordisk is firing up its first innovation challenge to scout out tech solutions in diabetes.
Move over, Siri and Alexa: There’s a new voice in town. Meet Sophia, Novo Nordisk’s first chatbot built specifically for people with diabetes.